Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01074073 · ClinicalTrials.gov registry record · Phase 1

Lithium Drug-Drug Interaction Study With Lurasidone HCl

A Phase 1 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01074073 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01074073, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.

Interventions

  • DRUG Lurasidone HCl

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-08
Est. Completion 2008-10
Phase Phase 1

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT01074073

The ClinicalTrials.gov registry entry for NCT01074073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.

NCT01074073 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01074073 about?

NCT01074073 is a clinical study titled "Lithium Drug-Drug Interaction Study With Lurasidone HCl". The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.

What is the current status of trial NCT01074073?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-08. Estimated completion is 2008-10.

What interventions are being tested in trial NCT01074073?

The interventions under investigation include: Lurasidone HCl (DRUG).

Who is sponsoring clinical trial NCT01074073?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.